Sino Biopharmaceutical (SBMFF) has received a new Buy rating, initiated by CMB International Securities analyst, Jill Wu.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jill Wu’s rating is based on Sino Biopharmaceutical’s impressive transformation towards innovation and its strong financial performance. The company has significantly increased its R&D investment, which now accounts for a substantial portion of its total revenue. This strategic focus has resulted in the approval of numerous innovative drugs, contributing significantly to the company’s revenue.
Furthermore, Sino Biopharmaceutical’s robust pipeline, particularly in oncology, showcases several promising candidates with global out-licensing potential. The rapid growth in biosimilar sales and the resilience of its generics business also provide a solid financial foundation. These factors, combined with the company’s strategic acquisitions and partnerships, underpin Jill Wu’s Buy rating with a target price of HK$9.40.
In another report released on July 21, CLSA also maintained a Buy rating on the stock with a HK$9.20 price target.